VEGFA and medullary thyroid gland carcinoma: In a phase II trial (75) enrolling 59 patients with advanced progressive MTC, an ORR of 36% was seen, both in patients with and without prior anti-VEGF therapy/conventional chemotherapy; the 6-month PFS was 67%.